For patients with newly diagnosed, standard-risk B-cell acute lymphoblastic leukemia (ALL) with an average or high r ...
Brexucabtagene autoleucel showed comparable efficacy outcomes in patients aged 60 to 69 with relapsed/refractory B-cell acute ...
For patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), obecabtagene autoleucel (obe-cel), an ...
Medical Watch Digest for Dec. 9 Acute lymphoblastic leukemia highest survival rate among pediatric cancers Survival rates for ...
Through the passing of his beloved father, standing alongside his daughter's battle with leukemia, and rebuilding a young ...
Adverse events associated with ponatinib in CML and ALL were shown to have decreased significantly since its approval, ...
MedPage Today on MSN5d
New Standard for Newly Diagnosed Pediatric B-Cell Acute Lymphoblastic LeukemiaSAN DIEGO -- Children with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) lived significantly longer without ...
The feud between Arcellx and Legend Biotech over their anti-BCMA CAR-T therapies for multiple myeloma is getting extra spicy ...
Long-term follow-up showed continued meaningful responses in patients with relapsed or refractory KMT2Ar acute leukemia who ...
Korea Joongang Daily on MSN10d
Homegrown leukemia treatment changes lives of five-year-old and his familyFive-year-old Lee Ji-han dreams of becoming a KTX high-speed train driver when he grows up. But those dreams were put on hold ...
News Medical on MSN13d
Scientists identify drug-resistant bone marrow cells linked to poor outcomes in fast-growing leukemiaIn a recent study published in Nature Cancer, researchers explore treatment resistance and relapse in T-cell acute ...
Ten years after its first FDA approval, Amgen’s Blincyto continues to make inroads in treating acute lymphoblastic leukemia. | Investigators halted study randomization early based on the strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback